This site is intended for UK healthcare professionals only


Boehringer Ingelheim and Lilly Alliance

Promotional webinar sponsored by Boehringer Ingelheim and Lilly Alliance
for UK HCPs.

This promotional webinar has been developed and funded by the Boehringer Ingelheim and Lilly Alliance for UK Healthcare Professionals only. Promotional information regarding Alliance products will be discussed in this webinar. The speakers have received an honorarium for giving this presentation.

On-demand video

Review of the new NICE NG28 guideline and how we can improve clinical outcomes for adults with type 2 diabetes

Review of the new NICE NG28 guideline and how we can improve clinical outcomes for adults with type 2 diabetes This promotional webinar was originally broadcast on 24 May 2022

This is a recording of the webinar. Please note that the speaker(s) are not able to answer questions from attendees watching the video on- demand.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).


Sign up

This resource has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company prior to the symposium. Editorial support for this symposium has been provided by OmniaMed Communications.

Primary Care Network Early Diagnosis Support

Stay up to date with our Primary Care Newsletter

Company profile

We are Boehringer Ingelheim.
Family-owned. Purpose-led. Innovation-driven: We work to improve health for people and animals.

Aspiring to make new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of need where we can do the most good.

By working collaboratively, we aim to accelerate the delivery of medical breakthroughs to help transform the lives of patients now, and for generations to come. In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.

We are committed to tackling the challenge of climate change. We serve local and global communities through our social impact programme and wevsupport social entrepreneurs who find healthcare solutions for the most vulnerable.

PC-GB-106589 | May 2022

PC-GB-106589 | May 2022
© Copyright Omniamed Communications. All Rights Reserved 108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom